2022 ESMO Congress Research Highlights
In the following videos, faculty from Dana-Farber Cancer Institute review research highlights from the ESMO Congress 2022 held in Paris, France, September 9-13, 2022.
Prostate Cancer Highlights from ESMO 2022
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the genitourinary cancer clinical updates you need to know from ESMO 2022
Medical Oncology
Medical Oncology
Bladder Cancer Highlights from ESMO 2022
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the genitourinary cancer clinical updates you need to know from ESMO 2022
Medical Oncology
Medical Oncology
Kidney Cancer Highlights from ESMO 2022
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the genitourinary cancer clinical updates you need to know from ESMO 2022
Medical Oncology
Medical Oncology
Testicular Cancer Highlights from ESMO 2022
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the genitourinary cancer clinical updates you need to know from ESMO 2022
Medical Oncology
Toni Choueiri, MD Shares the Latest Data From COSMIC-313
Kidney Cancer triplet slows progression in advanced disease when compared to immunotherapy combo (nivolumab + ipilimumab).
Medical Oncology
Glenn Hanna, MD Shares Phase 2 Study of Nivolumab for High-Risk Oral Leukoplakia
37% of patients with high-risk oral leukoplakia treated with preventative immunotherapy had proliferative leukoplakia regression and demonstrated favorable overall cancer-free survival.
Medical Oncology
Sara Tolany, MD Shares the Latest Breast Cancer Research
Results of monarcHER found abemaciclib + trastuzumab +/- fulvestrant was associated w/numerically improved overall survival when compared to chemo + trastuzumab among pts w/HR+, HER2+ advanced breast cancer.
Medical Oncology
Sara Tolaney, MD Shares New Study Results in Breast Cancer
Significant improvement in overall survival (OS) results seen in phase 3 TROPiCS study. Sacituzumab Govitecan improved OS from 11.2 months to 14.4 months compared to treatment of choice chemo.
Medical Oncology
The PATHFINDER study examined if a simple blood test could detect a cancer signal in people ages 50 years and older who were not known to have cancer.
Population Sciences
A phase I/II Trial investigating safety and efficacy of autologous TAC T cells targeting HER2 in response or refractory solid tumors.
Medical Oncology